Elevation Point Wealth Partners LLC Raises Stake in Thermo Fisher Scientific Inc. $TMO

Elevation Point Wealth Partners LLC increased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 105.9% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 15,725 shares of the medical research company’s stock after buying an additional 8,089 shares during the period. Elevation Point Wealth Partners LLC’s holdings in Thermo Fisher Scientific were worth $7,736,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of TMO. High Note Wealth LLC raised its holdings in shares of Thermo Fisher Scientific by 170.6% in the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock worth $27,000 after purchasing an additional 29 shares during the period. Swiss RE Ltd. bought a new position in Thermo Fisher Scientific during the fourth quarter valued at $28,000. Beacon Financial Strategies CORP bought a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at $29,000. Olistico Wealth LLC purchased a new position in shares of Thermo Fisher Scientific during the 4th quarter valued at $29,000. Finally, Birchwood Financial Partners Inc. bought a new position in shares of Thermo Fisher Scientific during the 4th quarter worth $29,000. 89.23% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $462.66, for a total value of $185,064.00. Following the sale, the chief operating officer owned 25,051 shares of the company’s stock, valued at $11,590,095.66. This trade represents a 1.57% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

TMO has been the topic of several recent research reports. HSBC downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and dropped their price objective for the company from $670.00 to $540.00 in a report on Wednesday, June 3rd. Wolfe Research assumed coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $535.00 price target on the stock. KeyCorp reaffirmed an “overweight” rating on shares of Thermo Fisher Scientific in a report on Tuesday, May 26th. Wall Street Zen cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Finally, DZ Bank assumed coverage on Thermo Fisher Scientific in a report on Friday, March 27th. They issued a “buy” rating and a $610.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and an average target price of $605.09.

Thermo Fisher Scientific Price Performance

TMO stock opened at $522.38 on Friday. The firm has a 50 day moving average of $473.02 and a 200-day moving average of $518.12. The company has a current ratio of 1.53, a quick ratio of 1.15 and a debt-to-equity ratio of 0.77. The firm has a market capitalization of $194.13 billion, a P/E ratio of 28.72, a price-to-earnings-growth ratio of 2.27 and a beta of 0.87. Thermo Fisher Scientific Inc. has a 12 month low of $403.36 and a 12 month high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, beating the consensus estimate of $5.25 by $0.19. The firm had revenue of $11.01 billion during the quarter, compared to the consensus estimate of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The business’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same period last year, the firm earned $5.15 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 24.84 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 15th. Investors of record on Monday, June 15th will be given a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 0.4%. The ex-dividend date is Monday, June 15th. Thermo Fisher Scientific’s payout ratio is presently 10.34%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.